Ulrik Niels Lassen
Clinical Professor
- Published
Patient information in phase 1 trials: A systematic review
Gad, K. T., Lassen, Ulrik Niels, Mau-Søerensen, M., Høybye, M. T. & Johansen, Christoffer, Mar 2018, In: Psycho-Oncology. 27, 3, p. 768-780Research output: Contribution to journal › Review › Research › peer-review
- Published
Socioeconomic Differences in Referral to Phase I Cancer Clinical Trials: A Danish Matched Cancer Case-Control Study
Gad, K. T., Johansen, Christoffer, Duun-Henriksen, A. K., Krøyer, A., Olsen, M. H., Lassen, Ulrik Niels, Mau-Sørensen, M. & Dalton, Susanne Oksbjerg, 1 May 2019, In: Journal of Clinical Oncology. 37, 13, p. 1111-1119Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
Garcia‐foncillas, J., Bokemeyer, C., Italiano, A., Keating, K., Paracha, N., Fellous, M., Marian, M., Fillbrunn, M., Gao, W., Ayyagari, R. & Lassen, Ulrik Niels, 2022, In: Cancers. 14, 7, 15 p., 1793.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer
Grunnet, M., Christensen, I. J., Lassen, Ulrik Niels, Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitlal, M., Wasan, H., Bridgewater, J., Valle, J. W. & Mau-Sørensen, M., Jul 2015, In: European journal of cancer (Oxford, England : 1990). 51, 11, p. 1381-8 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin
Hassan, R., Alewine, C., Mian, I., Spreafico, A., Siu, L. L., Gomez-Roca, C., Delord, J. P., Italiano, A., Lassen, Ulrik Niels, Soria, J. C., Bahleda, R., Thomas, A., Steinberg, S. M., Peer, C. J., Figg, W. D., Niederfellner, G., Méresse Naegelen, V. & Pastan, I., 2020, In: Cancer. 126, 22, p. 4936-4947 12 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan
Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M. & Lassen, Ulrik Niels, Aug 2010, In: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 118, 8, p. 585-94 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., 1 May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan
Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M. & Lassen, Ulrik Niels, 1 Aug 2010, In: Acta Pathologica Microbiologica et Immunologica Scandinavica. 118, 8, p. 585-94 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling
Hasselbalch, B., Lassen, Ulrik Niels, Poulsen, H. S. & Stockhausen, M., 1 Oct 2010, In: Cancer Investigation. 28, 8, p. 775-87 13 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 4952653
Most downloads
-
482
downloads
Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
224
downloads
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
175
downloads
Hallmarks of glioblastoma: a systematic review
Research output: Contribution to journal › Review › Research › peer-review
Published